GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Shiller PE Ratio

Xbrane Biopharma AB (OSTO:XBRANE) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xbrane Biopharma AB Shiller PE Ratio Historical Data

The historical data trend for Xbrane Biopharma AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Shiller PE Ratio Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xbrane Biopharma AB's Shiller PE Ratio

For the Biotechnology subindustry, Xbrane Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Shiller PE Ratio falls into.



Xbrane Biopharma AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xbrane Biopharma AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Xbrane Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.3/132.2054*132.2054
=-0.300

Current CPI (Mar. 2024) = 132.2054.

Xbrane Biopharma AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 100.541 0.000
201409 0.000 100.161 0.000
201412 -0.064 100.225 -0.084
201503 -0.521 99.950 -0.689
201506 -0.643 99.995 -0.850
201509 -1.976 100.228 -2.606
201512 -0.257 100.276 -0.339
201603 -0.160 100.751 -0.210
201606 -0.175 101.019 -0.229
201609 -0.210 101.138 -0.275
201612 -0.197 102.022 -0.255
201703 -0.197 102.022 -0.255
201706 -0.170 102.752 -0.219
201709 -0.164 103.279 -0.210
201712 -0.362 103.793 -0.461
201803 -0.167 103.962 -0.212
201806 -0.582 104.875 -0.734
201809 0.943 105.679 1.180
201812 -0.563 105.912 -0.703
201903 -0.584 105.886 -0.729
201906 -0.638 106.742 -0.790
201909 -0.298 107.214 -0.367
201912 -0.497 107.766 -0.610
202003 -0.381 106.563 -0.473
202006 -0.353 107.498 -0.434
202009 -0.339 107.635 -0.416
202012 -0.339 108.296 -0.414
202103 -0.262 108.360 -0.320
202106 -0.303 108.928 -0.368
202109 -0.207 110.338 -0.248
202112 -0.139 112.486 -0.163
202203 -0.163 114.825 -0.188
202206 -0.153 118.384 -0.171
202209 -0.189 122.296 -0.204
202212 -0.261 126.365 -0.273
202303 -0.100 127.042 -0.104
202306 -0.365 129.407 -0.373
202309 -0.315 130.224 -0.320
202312 -0.610 131.912 -0.611
202403 -0.300 132.205 -0.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xbrane Biopharma AB  (OSTO:XBRANE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xbrane Biopharma AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines